We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long-term aspirin use and cancer risk: a 20-year cohort study.
- Authors
Skriver, Charlotte; Maltesen, Thomas; Dehlendorff, Christian; Skovlund, Charlotte Wessel; Schmidt, Morten; Sørensen, Henrik Toft; Friis, Søren
- Abstract
Background Long-term use of aspirin has been shown to reduce colorectal cancer risk, but the association remains inconclusive for individual noncolorectal cancers. We examined the association between long-term aspirin use and cancer risk in Denmark. Methods Using nationwide registries, we followed individuals aged 40-70 years at baseline (January 1, 1997) for cancer diagnoses through 2018. We assessed low-dose (75-150 mg) aspirin use according to continuity, duration, and cumulative amount. In addition, we explored associations with consistent high-dose (500 mg) aspirin use. Using Cox regression, we estimated multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) with aspirin use for overall and site-specific cancer. Results Among 1 909 531 individuals, 422 778 were diagnosed with cancer during mean follow-up of 18.2 years. Low-dose aspirin use did not reduce the hazard ratio for cancer overall irrespective of continuity and duration of use (continuous use: HR = 1.04, 95% CI = 1.03 to 1.06). However, long-term (≥5 or ≥10 years) use was associated with at least 10% reductions in hazard ratios for several cancer sites: colon, rectum, esophagus, stomach, liver, pancreas, small intestine, head and neck, brain tumors, meningioma, melanoma, thyroid, non-Hodgkin lymphoma, and leukemia. Substantially elevated hazard ratios were found for lung and bladder cancer. In secondary analyses, consistent high-dose aspirin use was associated with reduced hazard ratios for cancer overall (HR = 0.89, 95% CI = 0.85 to 0.93) and for several cancer sites. Conclusion Long-term low-dose aspirin use was associated with slight to moderately reduced risks for several cancers but not for cancer overall owing to increased risk for some common cancers. Similar or slightly stronger inverse associations were observed for consistent use of high-dose aspirin.
- Subjects
DENMARK; ASPIRIN; DISEASE risk factors; HEAD &; neck cancer; COHORT analysis; NON-Hodgkin's lymphoma; BRAIN tumors
- Publication
JNCI: Journal of the National Cancer Institute, 2024, Vol 116, Issue 4, p530
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djad231